In the Democratic Republic of the Congo, more than 3,700 people have received the Ervebo vaccine in Ituri Province, where the Ebola outbreak is most active. The vaccination effort, part of a broader public health response, was expanded on Saturday as part of a new clinical trial called Bravo. The trial, led by Medecins Sans Frontieres (MSF) in collaboration with Congolese health authorities and the Africa Centres for Disease Control and Prevention, is being conducted in Bunia, the capital of Ituri.
The study aims to evaluate the effectiveness of the Ervebo vaccine in the local population. It includes healthcare workers, nurses, and other frontline staff involved in outbreak response. The initiative reflects a growing focus on both prevention and treatment as the outbreak continues to challenge public health systems. The vaccination campaign is part of a larger strategy to control the spread of the virus and protect vulnerable communities.
The expansion of the vaccination program comes amid ongoing efforts to manage the outbreak, which has affected multiple regions in the DRC. Health officials emphasize the importance of community engagement and rapid response to contain the virus. The trial is expected to provide critical data that could inform future vaccination strategies in the region.
